APACHEⅡ评分和降钙素原对肺部感染预后的预测作用被引量：54

Predictive value of APACHE Ⅱ score and procalcitonin in prognosis of patients with pulmonary infection

在线阅读下载PDF

导出

摘要目的探讨APACHEⅡ评分和降钙素原对重症监护室肺部感染患者预后的预测价值。方法收集2012年3月到2013年5月本院重症监护室肺部感染患者的临床资料，包括年龄、性别、APACHEⅡ评分、动脉血气、血沉、C-反应蛋白、乳酸、降钙素原、28d结局、ARDS发生情况等，绘制受试者工作特征曲线，比较APACHEⅡ评分和降钙素原对肺部感染患者28d结局及并发ARDS的预测价值。结果纳入患者78例，其中28d内死亡19例，1周内发展为ARDS33例。死亡组APACHEⅡ评分和降钙素原显著高于存活组，分别为[（23．3±7．5）椰（15．5±6．2），P〈0．001]和[18．6（1．5—25．0）ng/mLvs1．0（0．3—25．0）ng/mL，P=0．044]，氧合指数低于存活组，为[（189．7±89．4）YS（238．0±91．7），P=0．048]。ARDS组APACHEⅡ评分和降钙素原显著高于非ARDS组，分别为[（19．9±8．3）VS（15．6±6．0），P=0．013]和[8．3（1．2—25．0）ng／mLvs0．7（0．2—21．8）ng／mL，P=0．016]，氧合指数低于非ARDS组，为[（190．9±82．6）vs（252．1±92．4），P=0．003]。APACHEⅡ评分和降钙素原对28d结局有一定预测作用，APACHEⅡ评分的预测作用大于降钙素原（AUROC：0．797vs0．652，P=0．057）。APACHEⅡ评分和降钙素原对并发ARDS也有一定预测作用，两者预测作用相当（AUROC：O．651vs0．657，P=0．929）。APACHEⅡ评分和降钙素原联合后对28d结局及并发ARDS的预测作用较两者单独的预测作用无显著提高。结论APACHEⅡ评分和降钙素原可以作为肺部感染预后的预测指标，有助于临床早期甄别预后差及具有ARDS高危倾向的患者。 Objective To investigate whether acute physiology and chronic health evaluation II （APACHE ]] ） score and plasma procalcitonin are valuable predictors on the prognosis in patients with pulmonary infection. Methods Patients （n =78） with pulmonary infection in ICU from March 2012 to May 2013 were recruited from Xinqiao Hospital. The data including age, gender, APACHE II score, blood gas analysis, erythrocyte sedimentation, C-reactive protein, lactic acid, procalcitonin, mortality within 28 d, occurrence of acute respiratory distress syndrome（ ARDS）, and so on were collected and analyzed using the receiver operating characteristic curve. Results Among the 78 patients with pulmonary infection, 19 were death cases and 33 were ARDS cases. The statistical analysis showed that as compared to the survival group, APACHE II score and procalcitonin level were significantly higher while the oxygenation index was lower in the death group [23.3 ±7.5 vs 15.5 ±6.2, P〈0.001; 18.6（1.5 -25.0） vs 1.0（0.3 -25.0）ng/mL, P =0. 044; 189.7 ± 89.4 vs 238.0 ±91.7, P =0. 048, respectively]. Similarly, though both of APACHE II score and procalcito- nin level were also significantly higher and the oxygenation index was significantly lower in those who developed ARDS than in those who did not [19.9 ±8.3 vs 15.6 ±6.0, P =0.013; 8.3（1.2 -25.0） vs 0.7（0.2 - 21.8） ng/mL, P = 0. 016; 190.9 ± 82.6 vs 252.1 ± 92.4, P = 0. 003, respectively]. Additionally, the results revealed that APACHE II score or procalcitonin level could solely predicate the occurrence of ARDS （0. 651 vs0.657, P = 0. 929） and mortality within 28 d （0.797 vs O. 652, P = 0. 057）. However, no improvement was found when the two predictors were combined together. Conclusions Both APACHE II score and procalcito- nin level are valuable in predicting the prognosis of patients with pulmonary infection, and help identify patients with high risks of death or ARDS.

作者梅春霞刘娟徐智戢福云吴国明

机构地区第三军医大学新桥医院全军呼吸内科研究所

出处《第三军医大学学报》 CAS CSCD 北大核心 2014年第8期802-805,共4页 Journal of Third Military Medical University

基金国家自然科学基金面上项目(81070053)~~

关键词 APACHEⅡ评分降钙素原肺部感染 acute physiology and chronic health evaluation II score procalcitonin pulmonaryinfection

分类号 R44 [医药卫生—诊断学] R563.1 [医药卫生—呼吸系统]

作者简介吴国明，电话：（023）68774203，E-mail：guoming_wu@sina．com

引文网络
相关文献

参考文献19

1Ferguson N D, Frutos-Vivar F, Esteban A, et al. Clinical risk condi- tions for acute lung injury in the intensive care unit and hospital ward: a prospective observational study [ J ]. Crit Care, 2007, 11 (5) : R96.
2Brower R G, Lanken P N, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome[J]. N Engl J Med, 2004, 351(4) : 327 -336.
3National Heart, Lung and Blood Institute Acute Respiratory DistressSyndrome (ARDS) Clinical Trials Network. Randomized, placebo- controlled clinical trial of an aerosolized beta2 - agonist for treatment of acute lung injury[J]. Am J Respir Crit Care Med, 2011, 184(5) : 561 - 568.
4社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量：3072
5医院获得性肺炎诊断和治疗指南（草案）[J].中华结核和呼吸杂志,1999,22(4):201-208. 被引量：2169
6Ranieri V M, Rubenfeld G D, Thompson B T, et al. Acute respiratory distress syndrome: the Berlin de.'? nition[J]. JAMA, 2012, 307 (23) : 2526 -2533.
7Sheu C C, Gong M N, Zhai R, et al. The influence of infection sites on development and mortality of ARDS [ J ]. Intensive Care Med, 2010, 36(6) : 963 -970.
8Kojicie M, Li G, Hanson A C, et al. Risk factors for the development of acute lung injury in patients with infectious pneumonia [ J ]. Crit Care, 2012, 16(2) : R46.
9Toba A, Yamazaki M, Mochizuki H, et al. Lower incidence of acute respiratory distress syndrome in community-acquired pneumonia pa- tients aged 85 years or older [ J ]. Respirology, 2010, 15 ( 2 ) : 319 - 325.
10蒋军广,帖永新,谭伟丽,蒋丽红,翟建霞,王丽华.老年人重症肺部感染APACHE Ⅱ评分的临床价值[J].现代预防医学,2007,34(23):4420-4421. 被引量：7

二级参考文献159

1沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量：109
2刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量：790
3Kanai W, Oberhoffer M, Meier-Hellmann A, et al. Procalcitonin-A new indicator of the systemic response to severe infections[J]. Infection,1997,25(6):329-334.
4Gendrel D, Assicot M, Raymond J, et al. Procalcitonin as a marker for the early diagnosis of neonatal infection[J]. J Pediatr, 1996, 128(4): 570 -573.
5Peltola H, Jaakkola M. C-reactive protein in early detection of bactere verses viral infections in immunocompetent and compromised children[J]. J Pediatr, 1988,113(4):641-646.
6Monneret G, Labaune JM, Isaac C, et al. Procalcitonin and C-reactive protein levels in neonatal infections[J]. Acta Paediatr, 1997,86(2):209-212.
7Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
8de Roux A,Marcos MA,Garcia E,et al.Viral community-acquired pneumonia in nonimmunocompromised adults.Chest,2004,125:1343-1351.
9Ostrosky-Zeichner L,Alexander BD,Kett DH,et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.Clin Infect Dis,2005,41:654-659.
10Food and Drug Administration,HHS.Class Ⅱ Special Controls Guidance Document:serological assays for the detection of betaglucan.Fed Reqist,2004,69:56934-56936.